NEW YORK – GE Healthcare said Monday that it is joining with the University of Cambridge and Cambridge University Hospitals in the UK to develop an artificial intelligence-based application for precision cancer care.
The collaboration, which builds on earlier work at Cambridge supported by the Mark Foundation for Cancer Research and Cancer Research UK, will apply machine learning and other advanced software engineering techniques to produce this app. The partners will seek to integrate clinical, imaging, and genomic data from multiple sources into a single interface for oncologists, surgeons, radiologists, pathologists, and clinical nurse specialists to create personalized treatment plans for each patient.
Initially, GE Healthcare and Cambridge will evaluate the technology in ovarian cancer. They eventually hope to apply their creation across the UK and beyond.
"Bringing all this data together to make precise and informed decisions for patients can be hard. We often do this inefficiently and miss important connections between the data," Richard Gilbertson, director of the Cancer Research UK Cambridge Centre and head of oncology at the University of Cambridge, said in a statement.
"Aggregating and analyzing the substantial amounts of data available would help address an unmet need. Ovarian cancer is an important and complex disease with poor outcomes, and we believe this application would help us deal with its complexity," added James Brenton, professor of ovarian cancer medicine and a senior group leader at the Cancer Research UK Cambridge Institute. Brenton is also co-leader of the Mark Foundation Institute for Integrated Cancer Medicine.